Associate Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Steven P. Treon, MD
|
|
Give Review
Steven P. Treon works in the field of Oncology. He went to medical school at Boston University School of Medicine. Boston University School of Medicine has a rank of 30 in research and a 52 in primary care He received awards:"Super Doctor". Steven P. Treon, MD is also published. He has 101 publications published. The lastest publication: "Exome sequencing reveals recurrent germline variants in patients with familial Waldenstrom's macroglobulinemia.'
Publications
- Central Nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.
- Clonal B-cells in Waldenström's Macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.
- Exome sequencing reveals recurrent germline variants in patients with familial Waldenstrom's Macroglobulinemia.
- Rituximab intolerance in patients with Waldenström macroglobulinaemia.
- Incidence of secondary malignancies among patients with Waldenström Macroglobulinemia: An analysis of the SEER database.
- Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia.
- Extramedullary Waldenström Macroglobulinemia.
- The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4(Wild-type) and CXCR4(WHIM) mutated Waldenstrom mac...
- Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
- CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobu...
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related Disorders: consensus from the Seventh International Workshop on WM.
- The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macrogl...
- Transcriptional repression of plasma Cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia.
- Carfilzomib, rituximab and dexamethasone (CaRD) is active and offers a neuropathy-sparing approach for proteasome-inhibitor based therapy in Waldenstrom's macroglobuli...
- MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom's Macroglobulinemia.
- Detection of MYD88 L265P in peripheral blood of patients with waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
- Waldenström Macroglobulinemia: from biology to treatment.
- Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom's Macroglobulinemia.
- The genomic landscape of Waldenstom's Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associate...
- MYD88 L265P in Waldenstrom's Macroglobulinemia, IgM Monoclonal Gammopathy, and other B-cell Lymphoproliferative Disorders using Conventional and Quantitative Allele-Sp...
- MYD88 L265P somatic mutation in Waldenström's Macroglobulinemia.
- Molecular and Cellular effects of NEDD8 activating enzyme (NAE) inhibition in myeloma.
- Family history of non-hematologic Cancers among Waldenstrom macroglobulinemia patients: A preliminary study.
- Multiple Myeloma.
- Vorinostat induced Cellular stress disrupts the p38 mitogen activated protein kinase and extraCellular signal regulated kinase pathways leading to apoptosis in Waldens...
- Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containin...
- Long-term follow-up of symptomatic patients with lymphoplasmacytic Lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
- Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymo...
- Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobu...
- Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's Macroglobulinemia.
- Report From the Sixth International Workshop on Waldenström's Macroglobulinemia.
- Matrix metalloproteinase-8 is overexpressed in Waldenström's Macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27.
- Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia.
- Associated malignancies in patients with Waldenström's Macroglobulinemia and their kin.
- Hepcidin is produced by lymphoplasmacytic cells and is associated with Anemia in Waldenström's macroglobulinemia.
- Fcγ receptor predictive genomic testing and the treatment of indolent non-Hodgkin Lymphoma.
- Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
- Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits Immune function in multiple myeloma.
- Bortezomib as a treatment option in patients with Waldenström Macroglobulinemia.
- Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom Macroglobulinemia.
- Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom Macroglobulinemia.
- How I treat Waldenström Macroglobulinemia.
- Primary therapy of Waldenström Macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
- International prognostic scoring System for Waldenstrom macroglobulinemia.
- Long-term outcomes to fludarabine and rituximab in Waldenström Macroglobulinemia.
- Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's Macroglobulinemia.
- Soluble CD27 is a faithful marker of Disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenstr&Atil...
- Advances in the biology and treatment of Waldenström's Macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macro...
- Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's Macroglobulinemia.
- Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy.
- Endoplasmic reticulum stress is a target for therapy in Waldenstrom Macroglobulinemia.
- Increased incidence of transformation and myelodysplasia/Acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
- Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
- Lenalidomide and rituximab in Waldenstrom's Macroglobulinemia.
- Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to Disease progression in multiple myeloma and Waldenstrom macroglobulinemia.
- Thalidomide and rituximab in Waldenstrom Macroglobulinemia.
- CD27-CD70 interactions in the pathogenesis of Waldenstrom Macroglobulinemia.
- Targeting NF-kappaB in Waldenstrom Macroglobulinemia.
- Dual targeting of the proteasome regulates survival and homing in Waldenstrom Macroglobulinemia.
- Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's Macroglobulinemia.
- Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's Macroglobulinemia.
- Waldenstrom's macrogloblinemia/ lymphoplasmacytic Lymphoma.
- The Akt pathway regulates survival and homing in Waldenstrom Macroglobulinemia.
- Increased natural killer Cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F poly...
- Novel agents in the treatment of Waldenström's Macroglobulinemia.
- Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom Macroglobulinemia.
- Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's Macroglobulinemia: results of WMCTG Trial 03-248.
- Proteomic analysis of waldenstrom Macroglobulinemia.
- Molecular characterization of Waldenstrom's Macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences.
- Hepatitis C viral infection is not associated with Waldenström's Macroglobulinemia.
- Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.
- Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
- Hyperviscosity-related retinopathy in waldenstrom Macroglobulinemia.
- Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate exTracted from green tea: biologic activity and therapeutic implications.
- Infectious complications associated with alemtuzumab use for lymphoproliferative Disorders.
- CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell Disorders.
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia.
- Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
- Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple Myeloma: clinical implications.
- A SCID-hu in vivo model of human Waldenström Macroglobulinemia.
- Diagnosis and management of Waldenstrom's Macroglobulinemia.
- Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's Macroglobulinemia.
- CD5, CD10, and CD23 expression in Waldenstrom's Macroglobulinemia.
- Report of the Third International Workshop on Waldenstrom's Macroglobulinemia.
- CHOP plus rituximab therapy in Waldenstrom's Macroglobulinemia.
- Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's Macroglobulinemia.
- Clinical responses to sildenafil in Waldenstrom's Macroglobulinemia.
- Clonotypic IgM V/D/J sequence analysis in Waldenstrom Macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood.
- Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma Cells: clinical implications.
- Amyloidosis and Waldenström's Macroglobulinemia.
- Fluorescence imaging of multiple myeloma Cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
- CD40 induces human multiple myeloma Cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.
- Clinicopathological definition of Waldenstrom's Macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobuli...
- Defining Waldenstrom's Macroglobulinemia.
- Proteomic analyses in Waldenstrom's Macroglobulinemia and other plasma cell dyscrasias.
- Novel biologically based therapies for Waldenstrom's Macroglobulinemia.
- The malignant clone in Waldenstrom's Macroglobulinemia.
- Uniform response criteria in Waldenstrom's Macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
- Treatment recommendations in Waldenstrom's Macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
- Prognostic markers and criteria to initiate therapy in Waldenstrom's Macroglobulinemia: consensus panel recommendations from the Second International Workshop on Walde...
Schools
Boston University School Of Medicine
Boston University Med Center
Dana Farber Cancer Institute
Massachusetts General Hospital
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Bile Duct Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
Massachusetts General Hospital -
Boston University Medical Center -
Boston University School of Medicine
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Robert L. Schlossman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert H. Gottlieb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas J. Schuetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nikhil C. Munshi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Frank, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn Dranoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James A. Decaprio, MD |
|
|
Dr. George D. Demetri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susana M. Campos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold J. Burstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey I. Shapiro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ian E. Krop, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John G. Krikorian, MD
This Doctor is OpenDoctor Recommended.
|